New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Invitae Corporation
NVTA
Shape
US Flag

NYSE

Unprofitable

EPS improving

Unprofitable

EPS improving

5M

Medical - Diagnostics & Research

Next Earning date - 06 Nov 2024

5M

Medical - Diagnostics & Research

Next Earning date - 06 Nov 2024

0.02USD
Shape-0.01 ( -35.59%)
favorite-chart

Relative Strenght

0
favorite-chart

Volume Buzz

77%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

99%

Quote Panel

Shape
Updated October 15, 2024
1W % 1M % 3M % 1Y -97.53 %

Key Metrics

Shape
  • Market Cap

    5.44M


  • Shares Outstanding

    286.49M


  • Share in Float

    284.38M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    0.019


  • Average Volume

    12.70M


  • Beta

    1.589


  • Range

    0.015-2.34


  • Industry

    Medical - Diagnostics & Research


  • Website

    https://www.invitae.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

0.01x

P/S Ratio

-0.00x

P/B Ratio

-1.4

Debt/Equity

-299.1%

Net Margin

$-5.4

EPS

How NVTA compares to sector?

P/E Ratio

Relative Strength

Shape

NVTA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$592M

Shape9%

2025-Revenue

$1.48

Shape-24%

2025-EPS

$563M

Shape-9%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

J.P. Morgan

downgrade

Previous: Not converted

2022-08-10

Now: Underweight

Raymond James

downgrade

Previous: Outperform

2022-07-21

Now: Market Perform

Zacks Investment Research

downgrade

Previous: Not converted

2022-04-26

Now: Hold

Oppenheimer

upgrade

Previous: Not converted

2021-04-09

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

N/A

-0.81
vs -0.63

Q1.22

arrow
arrow

N/A

-0.78
vs -0.63

Q2.22

arrow
arrow

N/A

-0.68
vs -0.85

Q3.22

arrow
arrow

N/A

-0.42
vs -0.81

Q4.22

arrow
arrow

N/A

-0.34
vs -0.81

Q1.23

arrow
arrow

N/A

-0.37
vs -0.78

Q2.23

arrow
arrow

N/A

-0.30
vs -0.68

Q3.23

arrow
arrow

N/A

-0.10
vs -0.42

Q4.23

arrow
arrow

N/A

-0.30
vs -0.34

Q1.24

arrow
arrow

+526%

1.58
vs -0.37

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

+26%

126.1M  vs 100.4M

Q1.22

arrow
arrow

+19%

123.7M  vs 103.6M

Q2.22

arrow
arrow

+17%

136.6M  vs 116.3M

Q3.22

arrow
arrow

+17%

133.5M  vs 114.4M

Q4.22

arrow
arrow

-3%

122.5M  vs 126.1M

Q1.23

arrow
arrow

-5%

117.4M  vs 123.7M

Q2.23

arrow
arrow

-12%

120.5M  vs 136.6M

Q3.23

arrow
arrow

-9%

121.2M  vs 133.5M

Q4.23

arrow
arrow

+5%

128M  vs 122.5M

Q1.24

arrow
arrow

+24%

145.7M  vs 117.4M

Return on EquityShape

status-upQoQ

Q4.21

arrow
arrow

-7%

-0.07
vs -0.06

Q1.22

arrow
arrow

-6%

-0.06
vs -0.07

Q2.22

arrow
arrow

-654%

-6.54
vs -0.06

Q3.22

arrow
arrow

-190%

-1.90
vs -6.54

Q4.22

arrow
arrow

-98%

-0.98
vs -1.90

Q1.23

arrow
arrow

+524%

5.24
vs -0.98

Q2.23

arrow
arrow

+103%

1.03
vs 5.24

Q3.23

arrow
arrow

+87%

0.87
vs 1.03

Institutionnal OwnershipShape

status-upQoQ

Q2.22

arrow
arrow

279

279
vs 334

-16%

Q3.22

arrow
arrow

278

278
vs 279

0%

Q4.22

arrow
arrow

286

286
vs 278

3%

Q1.23

arrow
arrow

277

277
vs 286

-3%

Q2.23

arrow
arrow

237

237
vs 277

-14%

Q3.23

arrow
arrow

222

222
vs 237

-6%

Q4.23

arrow
arrow

209

209
vs 222

-6%

Q1.24

arrow
arrow

28

28
vs 209

-87%

Earnings Growth

Latest News